– GERMANY, Berlin – TME Pharma N.V. (EPA: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for the treatment of cancer by targeting the tumor microenvironment (TME), announced the appointment of Dr. Sandra Glucksmann (Ph.D.) to its Supervisory Board at the EGM on September 30, 2024.
“It is a great pleasure to welcome Alexandra to the supervisory board of TME Pharma at what is a significant and exciting time for the company,” said Dr. Maurizio PetitBon, Chairman of the Supervisory Board. “
“I am very pleased to be joining TME Pharma as a member of its supervisory board at this pivotal moment in the company’s journey. TME Pharma’s innovative approach to targeting the tumor microenvironment shows great promise in addressing aggressive cancers, and the glioblastoma program in particular presents a remarkable potential to transform the treatment paradigm for brain cancer patients, for whom the current standard of care offers no cure and very limited survival benefit.,” said Dr. Alexandra Glucksmann, Member of the Supervisory Board of TME Pharma. “I look forward to contributing to the company’s strategic direction as it advances its clinical programs and to working alongside the talented team at TME Pharma to help navigate the challenges and opportunities that lie ahead in bringing potentially life-changing therapies to patients in need.”
About TME Pharma
TME Pharma is a clinical-stage company focused on developing novel therapies for the treatment of the most aggressive cancers. The company’s oncology-focused pipeline is designed to act on the tumor microenvironment (TME) and the cancer immunity cycle by breaking tumor protection barriers against the immune system and blocking tumor repair. By neutralizing chemokines in the TME, TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. In the GLORIA Phase 1/2 clinical trial, TME Pharma is studying its lead drug candidate NOX-A12 in newly diagnosed brain cancer patients who will not benefit clinically from standard chemotherapy. TME Pharma has delivered top-line data from the NOX-A12 three dose-escalation cohorts combined with radiotherapy of the GLORIA clinical trial, observing consistent tumor reductions and objective tumor responses. Additionally, GLORIA expansion arms evaluate the safety and efficacy of NOX-A12 in other combinations where the interim results from the triple combination of NOX-A12, radiotherapy, and bevacizumab suggest even deeper and more durable responses and improved survival. US FDA has approved the design of a randomized Phase 2 trial in glioblastoma and TME Pharma was awarded fast-track designation by the FDA for NOX-A12 in combination with radiotherapy and bevacizumab for use in the treatment of aggressive adult brain cancer, glioblastoma. NOX-A12 in combination with radiotherapy had also previously received orphan drug designation (ODD) for glioblastoma in the United States and glioma in Europe. TME Pharma has delivered final top-line data with encouraging overall survival and safety profile from its NOX-A12 combination trial with Keytruda in metastatic colorectal and pancreatic cancer patients, which was published in the Journal for ImmunoTherapy of Cancer in October 2021. The company has entered its second collaboration with MSD/Merck for its Phase 2 study, OPTIMUS, to further evaluate the safety and efficacy of NOX-A12 in combination with Merck’s Keytruda and two different chemotherapy regimens as second-line therapy in patients with metastatic pancreatic cancer. The design of the trial has been approved in France, Spain, and the United States. The company’s second clinical-stage drug candidate, NOX-E36, is designed to target the innate immune system. TME Pharma is considering several solid tumors for further clinical development.
For more: https://www.tmepharma.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.